HER2CLIMB-05:图卡替尼联合曲妥珠单抗和帕妥珠单抗作为HER2阳性转移性乳腺癌一线维持治疗的III期研究
HER2CLIMB-05研究纳入654例诱导治疗后未进展的HER2阳性转移性乳腺癌患者,随机接受图卡替尼或安慰剂联合曲妥珠单抗/帕妥珠单抗维持治疗。总生存数据尚不成熟,安全性事件以腹泻和肝酶升高为主。
要点
- 图卡替尼联合方案显著改善一线维持治疗的PFS,中位PFS 24.9 vs 16.3个月
- PFS获益不受脑转移存在与否及激素受体状态影响
- 常见≥3级不良事件为腹泻(6.1%)、ALT升高(13.5%)和AST升高(7.1%)
核心结论
- 在曲妥珠单抗和帕妥珠单抗基础上加用图卡替尼作为HER2阳性转移性乳腺癌一线维持治疗,可显著改善无进展生存期,且未发现新的安全性信号。
研究设计与样本
- HER2CLIMB-05是一项III期随机对照研究(NCT05132582),纳入654例经中心确认的HER2阳性转移性乳腺癌患者,随机1:1接受图卡替尼300mg或安慰剂每日两次联合曲妥珠单抗/帕妥珠单抗。
主要发现
- PFS获益在有无脑转移及激素受体阳性或阴性亚组中均一致。
- 总生存数据尚不成熟。
关键数值与推荐
- 图卡替尼组最常见的治疗中出现的不良事件为腹泻(72.7%)、恶心(33.1%)、ALT升高(28.2%)和AST升高(25.8%)。
- 上述不良事件中≥3级的发生率分别为腹泻6.1%、恶心0.9%、ALT升高13.5%、AST升高7.1%。
- 图卡替尼组因不良事件停药的比例为13.5%。
临床怎么用
- 对于诱导治疗后未进展的HER2阳性转移性乳腺癌患者,可考虑在图卡替尼联合曲妥珠单抗和帕妥珠单抗作为一线维持治疗。
- 治疗期间需重点监测腹泻和肝酶升高,并做好相应管理。
局限性
- 总生存数据尚不成熟,需进一步随访。
- 研究排除了有症状脑转移的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). METHODS: Patients with centrally confirmed HER2+ MBC without evidence of progression post induction therapy and no or asymptomatic brain metastases (BM) were enrolled. Patients were randomly assigned 1:1 to tucatinib (300 mg) or placebo twice a day combined with trastuzumab/pertuzumab. The primary end point is investigator-assessed progression-free survival (PFS); secondary end points include overall survival (OS), PFS per blinded independent central review, CNS-PFS, and safety. RESULTS: Between March 2022 and July 2024, 654 patients were randomly assigned to tucatinib (n = 326) and placebo (n = 328) arms. All patients were female (median age, 54 years), 69.3% had de novo MBC, 52.6% were hormone receptor-positive, and 12.4% had presence/history of baseline BM. In this primary analysis, PFS was statistically significantly improved with addition of tucatinib versus placebo (hazard ratio, 0.641 [95% CI, 0.514 to 0.799]; P < .0001; median PFS: 24.9 v 16.3 months); a PFS benefit was seen regardless of the presence/absence of BM or hormone receptor status. OS data remain immature. The most common treatment-emergent adverse events (TEAEs) in the tucatinib arm were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (ALT: 28.2%; AST: 25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1%, respectively, were grade ≥3. In the tucatinib arm, 13.5% discontinued tucatinib because of TEAEs. CONCLUSION: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.
引用
- Dieras V, Curigliano G, Martin M, et al. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J Clin Oncol. 2025. PMID: 41369677. doi:10.1200/JCO-25-02600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。